OPEN ACCESS pISSN 2234-3180
eISSN 2234-2591

Table. 2.

Table. 2.

Oncologic outcomes according to LPLND status in rectal cancer patients after neoadjuvant chemoradiotherapy

Study Year Patients Local recurrence, % Free of distant metastasis, % 5-year overall survival, %




LPLND No LPLND LPLND No LPLND LPLND No LPLND LPLND No LPLND
Watanabe et al. [25] 2002 53 25 16.9 12 50.9 68
Ishihara et al. [9] 2016 14 34 - - - - CSS (HR, 0.73; 95% CI, 0.41–1.31)
Georgiou et al. [36] 2017 12 19 50 31.5 88.2 75 60.7 75.2
Nagawa et al. [26] 2001 23 22 4.3 0 69.5 77.2 - -
Akiyoshi et al. [27] 2014 38 89 2.6 7.8 - - 83.8 74.6
Ogura et al. [6] 2019 71 202 5.7* 25.6* 86.5* 69.2* 94.1*, 79.4*,
Matsuda et al. [37] 2018 32 13 20 0 74.7 78.6 - -

LPLND, lateral pelvic lymph node dissection; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; -, not applicable.

*Among patients with pretreatment short-axis diameter of ≥7 mm.

Cancer-specific survival.

5-Year relapse-free survival.

© Ewha Med J